cardiac stimulants excl. cardiac glycosides	is a	drug class
cardiac stimulants excl. cardiac glycosides	includes	β-adrenergic agonists
β-adrenergic agonists	activate	β1-adrenergic receptors
β1-adrenergic receptors	increase	heart rate
β1-adrenergic receptors	enhance	myocardial contractility
cardiac stimulants excl. cardiac glycosides	includes	dopamine
dopamine	acts on	dopamine receptors
dopamine	stimulates	cardiac output
cardiac stimulants excl. cardiac glycosides	includes	dobutamine
dobutamine	is a	synthetic catecholamine
dobutamine	primarily activates	β1 receptors
cardiac stimulants excl. cardiac glycosides	used for	acute heart failure
acute heart failure	may cause	hypotension
hypotension	requires	vasopressor support
cardiac stimulants excl. cardiac glycosides	contraindicated in	ventricular tachycardia
ventricular tachycardia	may lead to	cardiac arrest
cardiac stimulants excl. cardiac glycosides	increases	myocardial oxygen demand
increased myocardial oxygen demand	may cause	myocardial ischemia
myocardial ischemia	can progress to	myocardial infarction
cardiac stimulants excl. cardiac glycosides	monitored via	electrocardiogram
electrocardiogram	detects	arrhythmias
cardiac stimulants excl. cardiac glycosides	interacts with	MAO inhibitors
MAO inhibitors	may potentiate	hypertensive crisis
cardiac stimulants excl. cardiac glycosides	requires	dose titration
dose titration	prevents	adverse effects
cardiac stimulants excl. cardiac glycosides	administered via	intravenous infusion
intravenous infusion	allows for	rapid onset
cardiac stimulants excl. cardiac glycosides	metabolized by	liver enzymes
liver enzymes	may be affected by	drug interactions
cardiac stimulants excl. cardiac glycosides	excreted via	kidneys
kidney dysfunction	may require	dose adjustment
cardiac stimulants excl. cardiac glycosides	alternative to	cardiac glycosides
cardiac glycosides	have different	mechanism of action
cardiac stimulants excl. cardiac glycosides	used in	cardiogenic shock
cardiogenic shock	characterized by	low cardiac output
low cardiac output	leads to	organ hypoperfusion
cardiac stimulants excl. cardiac glycosides	may cause	palpitations
palpitations	may indicate	arrhythmia
cardiac stimulants excl. cardiac glycosides	contraindicated in	hypertrophic cardiomyopathy
hypertrophic cardiomyopathy	increases risk of	sudden death
cardiac stimulants excl. cardiac glycosides	requires	hemodynamic monitoring
hemodynamic monitoring	includes	arterial line
cardiac stimulants excl. cardiac glycosides	may worsen	pulmonary hypertension
pulmonary hypertension	increases	right ventricular afterload
cardiac stimulants excl. cardiac glycosides	shortens	hospital stay
shorter hospital stay	reduces	healthcare costs
cardiac stimulants excl. cardiac glycosides	interacts with	tricyclic antidepressants
tricyclic antidepressants	prolong	QT interval
prolonged QT interval	predisposes to	torsades de pointes
cardiac stimulants excl. cardiac glycosides	alternative to	phosphodiesterase inhibitors
phosphodiesterase inhibitors	have different	side effect profile
cardiac stimulants excl. cardiac glycosides	used with	vasodilators
vasodilators	reduce	afterload
afterload reduction	improves	cardiac output
cardiac stimulants excl. cardiac glycosides	contraindicated in	pheochromocytoma
pheochromocytoma	causes	catecholamine excess
cardiac stimulants excl. cardiac glycosides	requires	continuous ECG monitoring
continuous ECG monitoring	detects	ST-segment changes
cardiac stimulants excl. cardiac glycosides	may cause	anxiety
anxiety	may manifest as	restlessness
cardiac stimulants excl. cardiac glycosides	used in	postoperative care
postoperative care	focuses on	hemodynamic stability
cardiac stimulants excl. cardiac glycosides	metabolized via	COMT
COMT inhibitors	may prolong	drug effect
cardiac stimulants excl. cardiac glycosides	affects	blood pressure
blood pressure changes	may require	adjustment
cardiac stimulants excl. cardiac glycosides	alternative for	digoxin intolerance
digoxin intolerance	characterized by	nausea
cardiac stimulants excl. cardiac glycosides	may induce	tachycardia
tachycardia	may precipitate	myocardial ischemia
cardiac stimulants excl. cardiac glycosides	used in	septic shock
septic shock	associated with	vasodilation
cardiac stimulants excl. cardiac glycosides	requires	fluid resuscitation
fluid resuscitation	maintains	intravascular volume
cardiac stimulants excl. cardiac glycosides	interacts with	beta blockers
beta blockers	antagonize	adrenergic effects
cardiac stimulants excl. cardiac glycosides	may cause	tremors
tremors	are a	neurological side effect
cardiac stimulants excl. cardiac glycosides	alternative to	levosimendan
levosimendan	has different	calcium sensitizing mechanism
cardiac stimulants excl. cardiac glycosides	used in	cardiac surgery
cardiac surgery	requires	hemodynamic support
cardiac stimulants excl. cardiac glycosides	excreted as	metabolites
metabolites	may have	active properties
cardiac stimulants excl. cardiac glycosides	contraindicated in	coronary artery spasm
coronary artery spasm	reduces	myocardial perfusion
cardiac stimulants excl. cardiac glycosides	may increase	blood sugar
increased blood sugar	affects	diabetic patients
cardiac stimulants excl. cardiac glycosides	used with	diuretics
diuretics	reduce	fluid overload
cardiac stimulants excl. cardiac glycosides	alternative in	beta blocker overdose
beta blocker overdose	causes	bradycardia
cardiac stimulants excl. cardiac glycosides	requires	electrolyte monitoring
electrolyte imbalance	affects	drug response
cardiac stimulants excl. cardiac glycosides	may cause	headache
headache	may indicate	hypertension
cardiac stimulants excl. cardiac glycosides	used in	trauma patients
trauma patients	may experience	hemorrhagic shock
cardiac stimulants excl. cardiac glycosides	interacts with	cocaine
cocaine	potentiates	sympathomimetic effects
cardiac stimulants excl. cardiac glycosides	alternative for	chronotropic incompetence
chronotropic incompetence	limits	heart rate response
cardiac stimulants excl. cardiac glycosides	may reduce	mortality
reduced mortality	improves	patient outcomes
cardiac stimulants excl. cardiac glycosides	requires	ICU setting
ICU setting	provides	close monitoring
cardiac stimulants excl. cardiac glycosides	metabolized to	inactive compounds
inactive compounds	are	excreted renally
cardiac stimulants excl. cardiac glycosides	contraindicated in	aortic stenosis
aortic stenosis	limits	cardiac output
cardiac stimulants excl. cardiac glycosides	may cause	sweating
sweating	is a	autonomic response
cardiac stimulants excl. cardiac glycosides	alternative to	mechanical circulatory support
mechanical circulatory support	includes	ECMO
cardiac stimulants excl. cardiac glycosides	used in	drug-induced hypotension
drug-induced hypotension	may result from	anesthesia
